On March 8, 2022 Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics, reported it has been selected for an oral presentation of clinical data from its ongoing Phase 1/2 TRESR trial of RP-3500 and a poster presentation of initial discovery and validation data of the novel Synthetic Lethal Interactions for Precision Diagnostics (SNiPDx) panel to understand allelic status of STEP2 genes at the upcoming 2022 AACR (Free AACR Whitepaper) Annual Meeting, being held in New Orleans on April 8-13, 2022 (Press release, Repare Therapeutics, MAR 8, 2022, View Source [SID1234609711]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Oral Presentation Details on RP-3500 Phase 1/2 TRESR Trial Results:
Title: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
Presenter: Dr. Timothy Yap, MBBS, Ph.D., FRCP, Medical Director, Institute for Applied Cancer Science, Associate Professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas
Abstract Number: CT030
Session Title: Clinical Trials Minisymposium – Patient Selection Strategies for Molecularly Targeted Agents in Clinical Trials
Date/ Time: Monday, Apr 11, 2022 at 2:30 PM – 4:30 PM CT
Poster Presentation Details on SNiPDx Panel for Synthetic Lethal Drug Discovery:
Title: Detection of biallelic loss of DNA repair genes in formalin-fixed, paraffin embedded (FFPE) tumor samples using a novel tumor-only sequencing panel with error correction
Presenter: Dominik Glodzik, Ph.D., Repare Therapeutics, Instructor in Biomedical Informatics, Harvard Medical School
Abstract Number: 2801
Session Title: Diagnostic Biomarkers
Date/ Time: Tuesday, April 12, 2022 at 9:00 AM CT
About Repare Therapeutics’ SNIPRx Platform
Repare’s SNIPRx platform is a genome-wide CRISPR-based screening approach that utilizes proprietary isogenic cell lines to identify novel and known synthetic lethal gene pairs and the corresponding patients who are most likely to benefit from the Company’s therapies based on the genetic profile of their tumors. Repare’s platform enables the development of precision therapeutics in patients whose tumors contain one or more genomic alterations identified by SNIPRx screening, in order to selectively target those tumors in patients most likely to achieve clinical benefit from resulting product candidates.